Analysts expect Summit Therapeutics plc (NASDAQ:SMMT) to report $-0.35 EPS on April, 10.They anticipate $0.80 EPS change or 69.57 % from last quarter’s $-1.15 EPS. After having $-0.65 EPS previously, Summit Therapeutics plc’s analysts see -46.15 % EPS growth. The stock decreased 0.48% or $0.01 during the last trading session, reaching $2.09. About 41,791 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has declined 82.07% since March 17, 2018 and is downtrending. It has underperformed by 86.44% the S&P500.
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $67.25 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It has a 1.71 P/E ratio. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.
More notable recent Summit Therapeutics plc (NASDAQ:SMMT) news were published by: Globenewswire.com which released: “Summit Therapeutics plc : Interim 24-Week Data from PhaseOut DMD – GlobeNewswire” on January 25, 2018, also Benzinga.com with their article: “Earnings Scheduled For December 11, 2018 – Benzinga” published on December 11, 2018, Globenewswire.com published: “Update on Admission London Stock Exchange:SUMM – GlobeNewswire” on January 08, 2019. More interesting news about Summit Therapeutics plc (NASDAQ:SMMT) were released by: Globenewswire.com and their article: “Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018 – GlobeNewswire” published on October 03, 2018 as well as Nasdaq.com‘s news article titled: “Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference – Nasdaq” with publication date: March 14, 2019.